Fluidic device for producing platelets
09909102 · 2018-03-06
Assignee
- PLATOD (Paris, FR)
- ECOLE SUPÉRIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS (Paris, FR)
Inventors
- Dominique Baruch (Paris, FR)
- Antoine Pierre Marin Blin (Paris, FR)
- Aurelie Magniez (Villejuif, FR)
- Sonia Chassac (Ju-visy-sur-Orge, FR)
- Anne Le Goff (Paris, FR)
- Mathilde Reyssat (Antony, FR)
Cpc classification
C12N2501/125
CHEMISTRY; METALLURGY
A61K2035/124
HUMAN NECESSITIES
C12N2521/00
CHEMISTRY; METALLURGY
B01L3/502753
PERFORMING OPERATIONS; TRANSPORTING
B01L2300/0848
PERFORMING OPERATIONS; TRANSPORTING
A61P7/00
HUMAN NECESSITIES
B01L2200/0647
PERFORMING OPERATIONS; TRANSPORTING
B01L2400/086
PERFORMING OPERATIONS; TRANSPORTING
B01L2300/0861
PERFORMING OPERATIONS; TRANSPORTING
B01L3/502715
PERFORMING OPERATIONS; TRANSPORTING
B01L2200/0663
PERFORMING OPERATIONS; TRANSPORTING
B01L2300/16
PERFORMING OPERATIONS; TRANSPORTING
International classification
C12M3/00
CHEMISTRY; METALLURGY
B01L3/00
PERFORMING OPERATIONS; TRANSPORTING
Abstract
The invention relates to a fluidic device for producing platelets from a suspension of megakaryocytes or their fragments, comprising a production chamber comprising at least one channel in which a suspension of megakaryocytes is introduced to flow from its inlet to its outlet wherein said channel is textured with a plurality of obstacles on at least one portion of its inner surface. The invention is further directed to an ex vivo method for producing platelets from megakaryocytes using a fluidic device as defined above.
Claims
1. A fluidic device (1) for producing platelets from a suspension of megakaryocytes (5), comprising: a) a production chamber (3) comprising b) at least one channel (8) delimited by non-porous walls, c) at least one inlet opening (9) at one end in which a suspension of cells comprising megakaryocytes can be introduced and d) at least one outlet opening (10) at the other end, in which platelets can be collected; wherein at least one portion (11) of the inner surface of the walls of said channel (8) is textured with a plurality of obstacles.
2. The fluidic device according to claim 1, wherein said textured portion (11) of the inner surface of the channel (8) is further coated with a ligand with binding affinity for megakaryocytes.
3. The fluidic device according to claim 1, wherein the density, size and shape of said obstacles are determined so as to enable the capture of megakaryocytes on said textured portion of the inner surface of the channel for platelet shedding.
4. The fluidic device according to claim 1, wherein the obstacles are posts (12) or beams (15).
5. The fluidic device of claim 1, wherein said channel (8) has a substantially square or rectangular section.
6. The fluidic device of claim 1, wherein the obstacles are posts (12) with a substantially circular cross-section of a radius r, and said posts are arranged on the inner surface (13) of at least one portion of said channel to form a regular pattern with a hexagonal periodic structure, wherein: (i) the radius r is between 50 nm and 15 mm; (ii) the closest distance p between two post centers is equal to 100 nm; (iii) the angle a, which is the smallest angle defined by the longitudinal direction of the channel (14) and one of the lattice vectors of the hexagonal Bravais lattice is between 0 and 90; and (iv) optionally said posts have a height h<H, wherein H refers to the smallest distance measured between two opposite walls in a section of the channel.
7. The fluidic device according to claim 6, wherein said channel has a height H that is between 5 m and 1 mm.
8. The fluidic device according to claim 1, wherein said production chamber (3) comprises at least one or a plurality of parallel channels with a textured portion on their inner surfaces.
9. An ex vivo method for producing platelets from megakaryocytes, said method comprising: a) introducing a suspension of megakaryocytes into a fluidic device according to claim 1; b) subjecting said suspension to a flow under a shear rate suitable for elongation, fragmentation of the megakaryocytes and platelet release in the channel of the production chamber; and c) collecting platelets at the outlet of the channel.
10. The method according to claim 9, wherein the flow rate is fixed within a range that subjects said megakaryocytes in the textured portion of the channel to a maximum wall shear rate .sub.max not exceeding 30000 s.sup.1.
11. The method according to claim 9, wherein the collected platelets at the outlet of the channel further contain naked nuclei and/or intact megakaryocytes, said method further comprising the step of purifying, enriching or separating the platelets from said suspension.
12. The method according to claim 9, wherein said suspension is a suspension obtained by the following steps: (i) providing megakaryocyte progenitor and/or stem cells, (ii) expanding said megakaryocyte progenitor and/or stem cells, and, (iii) differentiating the expanded cells into megakaryocytes.
13. The method of claim 12, wherein the megakaryocyte progenitor and/or stem cells are selected from the group consisting of hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells.
14. The method according to claim 9, wherein said suspension of megakaryocytes is homogenized and/or purified prior to entering in the production chamber.
15. The method according to claim 9, wherein said platelets are sorted at the outlet of the channel by a method selected from the group consisting of cross flow filtration, laminar flow, dielectrophoresis, optical force, magnetic force, acoustic force, or inertial forces.
16. The method according to claim 9, wherein said platelets are functional platelets which can be activated like circulating blood platelets.
17. The fluidic device according to claim 2, wherein said ligand with binding affinity for megakaryocytes is selected from von Willebrand factor (VWF), or a biologically functional fragment thereof, or fibrinogen or fibronectin.
18. The method according to claim 10, wherein said maximum wall shear rate does not exceed 10000 s.sup.1.
19. The method according to claim 10, wherein said maximum wall shear rate does not exceed 8000 s.sup.1.
20. The method according to claim 10, wherein said maximum wall shear rate does not exceed 5000 s.sup.1.
21. The fluidic device according to claim 6, wherein the radius r is between 500 nm and 1.5 mm.
22. The fluidic device according to claim 6, wherein the closest distance p between two post centers is between 100 nm and 50 mm.
23. The fluidic device according to claim 6, wherein the closest distance p between two post centers is between 500 nm and 10 mm.
24. The fluidic device according to claim 6, wherein the closest distance p between two post centers is between 5 m and 1 mm.
25. The fluidic device according to claim 6, wherein one of the lattice vectors of the hexagonal Bravais lattice is between 0 and 30.
26. The fluidic device according to claim 8, wherein said production chamber comprises between 2 and 106 channels.
27. The method according to claim 18, wherein said maximum wall shear rate does not exceed 5000 s.sup.1.
Description
DESCRIPTIONS OF THE DRAWINGS
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15) (a) Single color flow cytometry analysis of platelet receptors, indicating the number of CD61, CD42b and CD49b receptors on the surface of platelets produced in the microfluidic device (black bars) and the control (light grey bars). MeansSEM (n=3) are provided and statistical analysis was performed using Student t-test for unpaired samples comparing receptor numbers in the microfluidic device vs control. The asterisk for CD42b histograms denotes a significant difference (p<0.05).
(b) Two-color flow cytometry analysis of platelet receptors, indicating the population of CD41.sup.+CD42b.sup.+ platelets produced in the microfluidic device vs the background values in the control.
(c and d) Two-color flow cytometry analysis of platelet receptors without or with activation of the CD41/CD61 receptor by the agonist peptide SFLLRN that stimulates the human PAR-1 thrombin receptor (TRAP). In
(16)
(17) (a) Indirect immunofluorescence labeling with anti-tubulin antibodies, revealed by a secondary AlexaFluor488 anti-mouse antibody and AlexaFluor546 phalloidin for F-actin staining is performed in the absence (top panels) or presence of thrombin (bottom panels) in samples produced by the fluidic device (left panels) or the control (right panels). Image acquisition was performed with an Axio Observer microscope (Zeiss) at 401.6-fold magnification with a QIClick-F-CLR-12 Digital CCD Camera (Q Imaging). Circular tubulin staining, characteristic of unactivated platelets is seen in the samples collected at the exit of the fluidic device (top left), whereas larger fragments without circular tubulin staining are recovered in samples collected from the control (top right). Actin stress fibers characteristic of activated platelets are seen in the samples collected at the exit of the fluidic device (bottom left), whereas larger elements without organized stress fibers staining are recovered in samples collected from the control (bottom right). Platelets are adherent to fibrinogen. The scale bar represents 5 m.
(b) Scanning electron microscopy images of platelets or elements recovered at the exit of the fluidic device (top left) and in samples collected from the control (right) in the absence (top panels) or presence of activation by agonist peptide SFLLRN that simulates the human PAR-1 thrombin receptor TRAP-1 (bottom panels). Each condition includes either adhesion to bovine serum albumin or fibrinogen. The scale bar represents 5 m.
(c) Aggregation in the presence of fibrinogen and CaCl.sub.2. Platelet aggregates are observed before (upper panels) or after activation with the agonist peptide SFLLRN that simulates the human PAR-1 thrombin receptor TRAP-1 (lower panels). Large aggregates are visible in the sample collected at the exit of the fluidic device (lower left panel). Fragments recovered in the control samples do not aggregate in the presence of the agonist peptide (lower right panel). The scale bar represents 10 m.
(18)
(19)
(20) In
(21) The production chamber 3 of a fluidic device is represented with more details in
(22) The texturing of the surface is created by a plurality of obstacles placed in the inner surface of at least a portion of the channel.
(23) According to one preferred embodiments, the obstacles are posts and are organized as shown in
(24) According to another preferred embodiments, the obstacles are beams and are organized as shown in
EXAMPLES
(25) Material and Methods
(26) CD34.sup.+ Cells Culture and Differentiation
(27) CD34.sup.+ cells were isolated from human umbilical cord blood (UCB) or peripheral blood by an immunomagnetic technique (Miltenyi Biotec, Paris, France) as previously reported (see Poirault-Chassac et al, Notch/Delta4 signaling inhibits human megakaryocytic terminal differentiation, Blood, vol. 116, no 25, p. 5670-5678, 2010). These blood samples were obtained after informed consent and approval from our Institute Ethics Committee and in accordance with the Declaration of Helsinki. CD34.sup.+ cells were cultured at 37 C. in 5% CO.sub.2 in complete medium consisting of Iscove modified Dulbecco medium (IMDM; GibcoInvitrogen, Saint-Aubin, France) supplemented with 15% BIT 9500 serum substitute (Stem Cells Technologies, Grenoble, France), -monothioglycerol (Sigma-Aldrich, Saint-Quentin Fallavier, France) and liposomes (phosphatidyl-choline, cholesterol and oleic acid; SigmaAldrich). Human recombinant stem cell factor (SCF, 10 ng/mL; Miltenyi Biotec) and thrombopoietin peptide agonist AF13948 (TPO, 50 nM) (see Dunois-Lard et al, Exposure of human megakaryocytes to high shear rates accelerates platelet production, Blood, vol. 114, no 9, p. 1875-1883, 2009) were added once at day 0 to the culture medium followed by addition of 20 nM TPO without SCF at day 7. Mature UCB megakaryocytes obtained after 12-14 days of culture were diluted in complete medium to a concentration of 0.7-1.210.sup.6 mL, thus approximately 10-fold less concentrated than in previously reported experiments. Measured mean diameter D.sub.cell was found to be 12.5+/1.7 m. Removal of platelets formed during culture and immediately prior to shear exposure was performed by means of a BSA gradient according to the methods reported in (Robert A, Cortin V, Gamier A, Pineault N. Megakaryocyte and platelet production from human cord blood stem cells. Methods Mol Biol. 2012; 788: 219-47). The concentration was then adjusted to 200 000 megakaryocytes/mL. Results are with megakaryocytes derived from UCB CD34.sup.+ unless specified otherwise.
(28) System Architecture
(29) A suspension of mature megakaryocytes is introduced in a 25 cm.sup.2 flask (Corning, USA) fixed on an orbital mixer (IKA MS3 basic), rotating at least at 300 rpm. The orbital mixer is used to maintain the homogeneity of the cell concentration in the suspension. The megakaryocytes concentration range in the flask is at least 100 mL.sup.1 and cannot exceed 1010.sup.6 mL.sup.1.
(30) Many methods can be used to control the flow through the different components: a differential pressure controller, a syringe pump and a peristaltic pump for example. When using a differential pressure control, an air pressure inlet and a suspension outlet are hermetically plugged into the cork of the flask. The air pressure is imposed in the flask by a pressure controller (MFCS-4C, Fluigent S.A., France). The flask is connected to the inlet of the microfluidic chip with Polyether ether ketone (PEEK) tubing (Upchurch Scientific, USA). Other tubing can be used (Tygon R-1000, Saint-Gobain, France, PTFE tubing, Saint Gobain, France for instance). The suspension is collected at the outlet. When using a peristaltic pump (Reglo, Ismatec, Switzerland), both inlet and outlet tubing arrive in the same rotating flask. The peristaltic pump can be plugged upstream or downstream from the microfluidic components. The megakaryocyte suspension flow can also be imposed by a syringe pump (PHD 2000, Harvard apparatus, US).
(31) Three microfluidic components are implemented in series: a megakaryocyte sorter and/or a lateral cell mixer upstream, a platelet production channel, and a cell sorter downstream, as depicted in
(32) Devices Fabrication
(33) Microfluidic components were made following a soft lithography rapid prototyping (Xia et al. 1998. Soft lithography. Annual Review of Materials Science. vol. 28, no 1, p. 153-184). First, transparencies were produced from a computer assisted design file containing the design of microchannels. These transparencies were used as masks in transferring the pattern into negative photo resist (SU-8 2000 and 3000 series, Microchem, US) by conventional photolithography, yielding a master with positive relief of micro channels. Both channels were made from molded polydimethylsiloxane (PDMS, Sylgard, Dow Corning, USA), sealed on glass slides. PDMS prepolymer and curing agent were mixed and degassed. The mixture was poured onto the master, cured for 2 h at 70 C., cut into individual chips, and inlet and outlet holes were punched. Glass slides were cleaned with isopropanol and dried. Both PDMS individual structures and glass slides were treated in an oxygen plasma oven and then sealed.
(34) Platelet Production Channels
(35) The textured surface is defined by 3D patterns on the channel walls (glass or PDMS). Herein we present two examples of these possible patterns: a hexagonal array of disks in the (Oxy) plane and a 1D array of beams in the (Ox) direction. The geometries of those patterns are described in
(36) Three different channel geometries were used in this example, illustrated in
Shear Rates
(37) We define a surface element on the channel wall, whatever on glass or PDMS (including PDMS obstacles). On this surface element, we define the unit vector of a plane by the vector acting normal to it, {circumflex over (n)}. A unit vector {circumflex over (m)}, tangential to the surface and in the local direction of the fluid velocity v, is determined so that ({circumflex over (n)}, {circumflex over (m)}) is a planar Cartesian coordinate system. The wall shear rate {dot over ()}(in s.sup.1) is then defined by
(38)
The wall shear rate is controlled by both the flow rate in the device and by the geometry of the device. The hydrodynamic resistance of the entire fluidic system was characterized by imposing pressure differences between the inlet and the outlet, by means of a pressure controller, and by measuring the resulting flow rate (Flowell, Fluigent, France).
Videomicroscopy System
(39) The microfluidic chip was set on the stage of an inverted microscope (DMI6000 B, Leica Microsystems GmbH, Germany). A computer assisted motorized stage control was used to record positions along the channel length. We recorded observation field positions and alternated recording images between them along the experiment time. Differential interference contrast objective was used to record movies and images between 10 and 40. A CMOS high-speed camera (Fastcam SA3, Photron, USA) was used to record images at frequencies from 0.5 to 1500 Hz.
(40) Surface adherent cells were counted manually from the recorded channel images, and cells in suspension were counted both with a hematocytometer and a coulter counter (Scepter II, Millipore, US) when sampled in bulk.
(41) Protein Surface Treatments
(42) Human von Willebrand factor (VWF) was a gift of Laboratoire Franais du fractionnement et des Biotechnologies. It was diluted at 40 g.Math.mL.sup.1 in phosphate buffered saline phosphate buffered saline (PBS) without calcium and magnesium ions (Lonza, Belgium), and perfused in sealed microchannels. We used this surface coating only in the platelet production channel.
(43) Bovine serum albumin (Sigma-Aldrich La Verpilleres, France) was diluted at 40 g.Math.mL.sup.1 in phosphate-buffered saline (PBS) and perfused in microchannels.
(44) For both protein treatments, inlets and outlets of the chips were covered by cover slips. The chips were incubated overnight at 4 C. and washed with PBS before the experiment. VWF adsorption on both glass and PDMS was verified by fluorescence labeling with a primary polyclonal rabbit anti-vWF antibody (Dako, 10 g.Math.mL.sup.1) and with a secondary Alexa fluor 546 polyclonal goat anti-rabbit antibody.
(45) Cell Mixer
(46) The design of the mixer is directly inspired from the herringbone-like structure of the chaotic mixer for microchannels disclosed by Stroock et al. (Chaotic Mixer for Microchannels, Science, vol. 295, no 5555, p. 647-651, 2002). Considering Stroock et al parameters, the cell mixer design was made with h=50 m, w=300 m, =1, p= or and q=0.63 m.
(47) Parallelization of Platelet Production Channels
(48) A high megakaryocyte flow rate into the device is desired to increase the platelet production number. For a given pattern of obstacles and height of the channel, the cell flow rate can be increased by increasing the channel width. As mechanical constraints of the PDMS channels impose a maximum width over height ratio to avoid channel collapse, we parallelized channels to increase the effective width.
(49) Megakaryocytes were introduced in the platelet production channel by means of tubing. Cells were distributed in the parallel channel through a triangular shaped entrance, which brings the cells to every channel (
(50) To avoid imposing a wall shear rate that could damage the cells, the distribution channel is fabricated using a higher height than the one used in the parallelized shear channels. The ratio of these two heights is typically between 2 and 20.
(51) Platelet Sorting
(52) Naked nuclei and intact megakaryocytes can be removed from the platelets by sorting in serial the outflow suspension from the platelet production channel, as depicted in
(53) Characterization of Collected Platelets
(54) Platelet production in the microfluidic device of geometry 3 was compared to control samples, consisting of tubings without the microfluidic chips. Expression of CD41 and CD42 antigens was characterized using a flow cytometer BD Fluorescence Activated Cell Sorter (FACS) Calibur (BD Biosciences, Le Pont de Claix, France). Platelets were incubated with fluorescein isothiocyanate (FITC)-conjugated anti-human CD41 (IIb) and R-phycoerythrin (PE)-conjugated anti-human CD42b (GPIb) (both from Beckman Coulter, Villepinte, France) and FITC-conjugated anti-human activated IIbb3 (BDBiosciences) during 15 minutes at 22 C. Controls were performed using FITC mouse IgG.sub.1 (Beckman Coulter), PE mouse IgG.sub.1 (Beckman Coulter). Single color flow cytometric analysis of platelet receptors was performed using the GP screen assay (Biocytex, Marseille, France). The number of antigenic sites is determined by converting the fluorescence intensity into corresponding numbers of monoclonal antibodies bound per platelet based on a calibrated bead standard curve. Fibrinogen adhesion assay and epifluorescence characterization were performed as reported in as previously reported in the above-cited publication of Dunois-Lard, except that activation was obtained in the presence of thrombin or of an agonist peptide of the PAR-1 thrombin receptor. Epifluorescence was analyzed at 494 nm and 522 nm (absorption and emission, respectively), using a high-resolution bioimaging platform (EMCCD MGi Plus Qimaging Rolera camera, Roper Scientific, Evry, France). Scanning electron microscopy was performed by adding platelets on glass slides coated with 2% BSA or fibrinogen (0.2 mg/ml) during 30 min. Thereafter, a drop of a solution containing HEPES 50 mM NaCl, 135 mM Ca.sup.2+, 2 mM PFA 2%, and glutaraldehyde 4% was added on the slides for platelet fixation, and then the slides were incubated overnight in a bath containing the same solution. The day after, samples were washed and dehydrated with ethanol at 25%, 50%, 75%, 95% and finally at 100% then dried by air vacuum. Aggregation was performed using a dual-channel Whole Blood/Optical Lumi-Aggregometer (Model 700 Chrono log Corporation).
(55) Megakaryocyte Mixing
(56) The herringbone grooves create chaotic microvortices in the (Oyz) plane of the channel leading to lateral displacement of the cells (
(57) Megakaryocyte Capture
(58) We define captured megakaryocytes by surface adherent megakaryocytes, independently of their translocation velocity (including non moving cells). We evaluated the megakaryocyte capture according to the different geometries of beams or posts (defined in
(59) Along the last part that follows the textured portion and is empty of obstacles, we observe a sharp density difference between the textured channel (250 mm.sup.2) and the non-textured channel (<10 mm.sup.2). This is a direct consequence of the capture occurring in part 2 coupled with the translocation speeds of megakaryocytes (the distribution of translocation speed spreads from 0 m.Math.s.sup.1 to 200 m.Math.s.sup.1).
(60) Effect of the Protein Surface Coating
(61) On the vascular endothelial cells, VWF allows translocation of circulating platelets when subjected to high shear rates (>1000 s.sup.1) through binding of their GPIb receptors (Huizinga et al, Structures of Glycoprotein Ib and Its complex with von Willebrand Factor A1 Domain, Science, vol. 297, no 5584, p. 1176-1179, 2002). In vitro, the adsorption of VWF allows megakaryocytes, platelets and proplatelets to translocate on the PDMS and glass surface (Dunois-Lard et al, Exposure of human megakaryocytes to high shear rates accelerates platelet production, Blood, vol. 114, no 9, p. 1875-1883, 2009). We compared the effect of VWF and BSA coating on the adhesion of megakaryocytes on the channel walls.
(62) We performed four experiments with the channel geometry 2, coated with VWF and four experiments with channel geometry 2, coated with BSA. We compared the surface density of megakaryocytes at t=50 min.
(63) Results are shown in
(64) A third set of experiments has been done with fibrinogen coating. Although fibrinogen is known to bind megakaryocytes at a low shear rate, it was not possible to observe megakaryocyte capture at the high shear rates that were used to promote megakaryocyte elongation.
(65) Those results do not describe the behavior of the cells on the surface in detail. We qualitatively observe an important decrease of a with distance along the x axis within the non-textured channel. In the textured channel, we observe a slight increase followed by a decrease of a along the textured length. These results are transient and result from the different transport mechanisms of the megakaryocytes.
(66) Megakaryocyte and Platelet Transport
(67) A cell owns two different transport modes: advection, yielding a speed of several mm.Math.s.sup.1, and translocation, yielding a speed of several m.Math.s.sup.1.
(68) Megakaryocyte Ruptures and Platelet Release
(69) We observed platelet shedding from surface adherent megakaryocytes. When megakaryocytes are translocating on the channel walls, they establish transient interactions with VWF on the wall surface, which progressively lead to morphologic changes until platelet shedding from megakaryocytes. Shedding occurs when both elongation and cell body are translocating. This process is described in the above-cited publication of Dunois-Lard and in the international patent application WO 2010/06382311. After a rupture, both entities continue translocating on the wall surface.
(70) Shedding also occurs when the cell body translocates until being trapped around or behind a post (
(71) The amount of platelets that can be released by each megakaryocyte can be estimated by long-time imaging of a single cell. Our observations showed that a megakaryocyte trapped on a post and subjected to shear can release 11 fragments/hour. These fragments have the shape of beads on a thread. We measured the size distribution of the released beads, fitting each of them as an ellipse on the frames of the video. Assuming revolution symmetry, we estimated the total volume of released beads and divided it by the volume of the smallest observed bead that we assume to be a platelet. With this method, we find a platelet yield of up to 350 platelets per megakaryocyte. In comparison, a human megakaryocyte is expected to convert in vivo into 10.sup.2-10.sup.3 platelets (Thon et al, Cytoskeletal mechanics of proplatelet maturation and platelet release, J Cell Biol, vol. 191, no 4, p. 961-874, 2010, and Thon et al., Platelet Formation, Seminars in Hematology, vol. 47, no 3, p. 220-226, 2010).
(72) Parallelization of Platelet Production from Megakaryocytes
(73) We amplified the process of platelet production by fabricating parallelized channels patterned with arrays of pillars. All the following experiments used the geometry 3 described above. Geometry 3 owns a total of 168 770 pillars.
(74) In a microfluidic device configuration, a 20 mL agitated megakaryocyte suspension (200 000 megakaryocytes/mL) was circulating in closed-loop through 5 parallel devices fabricated following geometry 3 for 2 hours. In a control configuration, a 20 mL agitated megakaryocyte suspension was circulating in closed-loop without any microfluidic device in a single tubing (Tygon, 0.57 mm I.D., Saint-Gobain, France). To quantify platelet production, cell suspensions collected at the beginning and after 120 min perfusion either through the microfluidic device, or through the control system, were counted in a hemocytometer. Birefringent cells with a diameter between 1 m and 4 m were considered as platelets.
(75) Characterization of Platelet Produced in the Fluidic Device
(76) After two hours of perfusion, the cell suspension circulating in the device contained larger amounts of platelets than that circulating in the control system. These platelets can then be sorted by the different methods described above. Platelets produced in the fluidic device displayed several characteristics that were comparable to those of natural platelets, i.e. platelets isolated from blood or circulating blood platelets. We found that these features are missing from the samples obtained from the control system consisting of all elements except for the fluidic channel. As shown on